Drug Profile
OPC 64005
Alternative Names: OPC-64005Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator Lundbeck A/S; Otsuka America Pharmaceutical
- Developer Otsuka America Pharmaceutical
- Class Antidepressants; Behavioural disorder therapies
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Major depressive disorder
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 07 Dec 2022 Phase II development in Major depressive disorders is still ongoing in Japan (PO) (Otsuka America Pharmaceutical pipeline, December 2022)
- 25 Feb 2022 Otsuka Pharmaceutical completes a phase-II clinical trial in Major depressive disorder in Japan (PO) (NCT04244253) (JapicCTI-205116)
- 26 Aug 2020 Discontinued - Phase-II for Attention-deficit hyperactivity disorder (In adults) in USA (PO) (Otsuka pharmaceutical pipeline August 2020)